

NEWS RELEASE

[Home](#)[Company](#)[Technology](#)[Services](#)[Client Profiles](#)[Online Library](#)[Contact Us](#)

Non-Invasive Medical Technologies, Inc., dba In-Line Diagnostics Corporation, Granted FDA Clearance for Hemodialysis Access Flow Technology

BOSTON, MA - December 22, 2000 - In-Line Diagnostics Corporation announced today that the Transcutaneous Access Flow (TQa™) device indicated for the transcutaneous estimation of access blood flow received FDA 510(k) clearance for sale in the U.S.

The TQa technology provides the real-time determination of vascular access blood flow rate based on relative changes in hematocrit (red cell volume). This new technique eliminates the need for dialysis line reversal. The TQa product feature will serve as a complementary product to the base Crit-Line™ platform offered by In-Line Diagnostics. The Crit-Line is a non-invasive stand-alone blood monitoring system employing proprietary photo-optical technology which enables the continuous real-time measurement of vital whole blood parameters such as hematocrit, percent change in blood volume and oxygen saturation.

"We debuted our transcutaneous access blood flow device at the 2000 American Society of Nephrology Meeting in Toronto where it was met with extremely positive reviews. As a complement to the Crit-Line, the TQa will revolutionize the access blood flow market due to its minimal test time, accuracy, ease of use, and elimination of line reversal requirements," said Michael Magliochetti, Ph.D., President & CEO of In-Line Diagnostics. "This new offering is the first of several add-on products which will continually build upon the Crit-Line platform."

In-Line Diagnostics is a privately held medical technology company with offices in both Boston and Salt Lake City. In-Line Diagnostics has established a product portfolio encompassing both extracorporeal and transcutaneous blood parameter monitoring. For more information about In-Line Diagnostics, call 800-546-5463 or visit us at www.crit-line.com.

Contact:

Patrick Moriarty
In-Line Diagnostics Corporation
Wannalancit Technology Park 175 Cabot St., Suite 306
Lowell, MA 01845
978-275-4172